AMR Benchmark 2026: Progress Against Superbugs Urged

The 2026 AMR Benchmark report released by the Access Medicine Foundation identifies progress in the fight against antimicrobial resistance (AMR) but emphasizes the need for faster action to enhance access to medicines and strengthen health systems. The report notes that drug-resistant infections result in approximately four million deaths globally each year, with projections indicating that this number could rise to nearly two million annually by 2050.

Despite some advancements by pharmaceutical companies in developing new treatments and improving access to existing antibiotics, the report expresses concern over a decline in overall industry performance since the previous benchmark in 2021. It highlights that seven late-stage antimicrobial projects show genuine innovation potential.

Notably, GSK's gepotidacin, a new antibiotic for treating uncomplicated urinary tract infections, represents the first new oral antibiotic class for such infections in nearly 30 years. The report underscores the urgent need for stronger health systems, particularly in Africa, where infectious diseases remain prevalent.